Health Blueprint

Back to Longevity News

News summary

Humacyte begins first-in-human coronary bypass trial

Source: Longevity Technology • Published: 10 Nov 2026, 11:31

Summarized by Masters of Longevity from Longevity Technology.

A Phase 2a trial is testing Humacyte's investigational CTEV in bypass patients.

Humacyte begins first-in-human coronary bypass trial
Key Takeaways
  • Humacyte launched a Phase 2a study testing CTEV as grafts.
  • The CTEV is an acellular small-diameter vessel designed for recellularization.
  • Preclinical porcine and ovine work showed patency and host recellularization.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickPlan Your Health Tests in Three MinutesThe free Personal Health Diagnostics Planner turns a short questionnaire into a ranked, personalised PDF: a clearer starting point for deciding which health checks deserve attention now.MoL PickCan You Really Measure Whether You’re Aging More Slowly?A younger epigenetic-age score can look like proof that an intervention is working. A major new analysis shows which clocks detect change—and why movement is not yet the same as longer healthspan.MoL PickBiotin for Hair Growth: The Weak Evidence—and the Blood-Test Risk Most People MissBiotin deficiency can affect hair. That does not mean more biotin makes healthy hair grow—and high doses can distort important laboratory results.